Skip to content
naulon
Not checkedNot checked for notices yet.

Carbon-based ruthenium nanomaterial-based electroanalytical sensors for the detection of anticancer drug Idarubicin

S. Irem Kaya, Sevinc Kurbanoglu, Ejmer Yavuz and 3 more

Scientific Reports · 2020

doi:10.1038/s41598-020-68055-6 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Abstract In this work, a novel nanosensing platform was suggested based on ruthenium for the sensitive determination of Idarubicin anticancer drugs. Ruthenium/Vulcan carbon-based nanoparticles were synthesized ultrasonication method and then characterized by transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), and X-ray diffraction (XRD). The mean particle size of the nanoparticles calculated by the TEM analysis was found to be 1.98 nm ± 0.29 nm, and the Ru nanoparticles were mostly dispersed on the support material. Glassy carbon electrode (GCE) surface was modified with Ruthenium/Vulcan carbon-based nanomaterials (Ru@VC), and characterization of the nanosensor was performed using electrochemical impedance spectroscopy and cyclic voltammetry. The limit of detection (LOD) and limit of quantification (LOQ) values were found as 9.25 × 10–9 M and 2.8 × 10–8 M in buffer samples. To demonstrate the applicability and validity of developed nanosensor, it was used for the determination of Idarubicin in Idamen® IV (10 mg/10 mL vial) and human serum sample. The results of recovery studies showed that the Ru@VC/GCE nanosensor was free from excipient interferences in the dosage forms of injection, and it can be successfully applied to biological samples.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.